Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124 wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
Title: “Targeting an Intracellular Oncoprotein in MHC 1 for Immunotherapy” Presented by: Charles Craik, PhD Professor, Departments of Pharmaceutical Chemistry, Pharmacology, and Biochemistry/Biophysics, UCSF Associate Director for Translational Laboratory Research and Co-leader, Molecular Oncology Program, Helen Diller Family Comprehensive Cancer Center Sponsor: Michael B. Atkins, MD Lecture Series Presented by Georgetown Lombardi Comprehensive […]
For patients with treatment-naive BRAFv600 mutant metastatic melanoma, treatment first with combination nivolumab/ipilimumab yields better overall survival than dual BRAF/MEK inhibition with dabrafenib/trametinib.